Table 3. Duration, dose and timing of ERT in the analyzed treated patients.

age (years)	body weight (kg)	ERT product and dose/2 weeks	interval from last ERT dose to urine sampling (days)	treatment duration (years)	biomarker score
62	72	agalsidase alfa 0.22 mg/kg	13	0.6	−1.999 (neg)
28	60	agalsidase alfa 0.18 mg/kg	1	3.6	−1.436 (neg)
25	49	agalsidase alfa 0.21 mg/kg	7	3.8	−1.129 (neg)
17	51	agalsidase alfa 0.20 mg/kg	13	2.4	−0.601 (neg)
43	51	agalsidase alfa 0.28 mg/kg	5	1.1	−0.563 (neg)
59	52	agalsidase alfa 0.20 mg/kg	2	5.6	−0.313 (neg)
22	59	agalsidase alfa 0.20 mg/kg	7	5.6	−0.245 (neg)
34	63	agalsidase alfa 0.22 mg/kg	6	0.1	0.060 (neg)
33	55	agalsidase beta 1.27 mg/kg	13	6.4	0.241 (pos)
20	45	agalsidase alfa 0.20 mg/kg	1	5.9	0.316 (pos)
57	58	agalsidase alfa 0.12 mg/kg	17	2.3	0.455 (pos)

ERT, enzyme replacement therapy. The diagnostic cut off value for the biomarker score is 0.1.